Position in EXEL
as of Jun 30, 2026
· filed Aug 5, 2026
Position Value
$22,275,018
+$4,950,118 QoQ
Shares Held
409,392
+1.4% QoQ
Ownership
0.165%
of shares outstanding
% of Portfolio
2.73%
of 13F equity value
Holder Rank
#86
of 756 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026South Street Advisors LLC holds $40,957,206 across 2 Biotechnology names. EXEL ranks #1 (54.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | EXEL |
Exelixis, Inc.
This page
|
409,392 | $22,275,018 | |
| 2 | HALO |
Halozyme Therapeutics, Inc.
|
238,689 | $18,682,188 |
All Filings in EXEL
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $22,275,018 | 409,392 | Shares | Sole | 2026-08-05 | |
| 2026-03-31 | $17,324,900 | 403,938 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $17,834,821 | 406,909 | Shares | Sole | 2026-02-10 | |
| 2025-09-30 | $17,601,275 | 426,181 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $8,243,621 | 187,015 | Shares | Sole | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||